

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

Brilliant Violet 421(TM) anti-mouse CD3

RRID:AB_2562553

Type: Antibody

Proper Citation

BioLegend Cat# 100228, RRID:AB_2562553

Antibody Information

URL: http://antibodyregistry.org/AB_2562553

Proper Citation: BioLegend Cat# 100228, RRID:AB_2562553

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2562553

Vendor: BioLegend

Catalog Number: 100228

Alternative Catalog Numbers: 100227

Record Creation Time: 20250820T001813+0000

Record Last Update: 20250820T075506+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. *iScience*, 28(5), 112508.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. *Cancer cell*, 43(5), 823.

Mout R, et al. (2025) Design of soluble Notch agonists that drive T cell development and boost immunity. *Cell*.

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. *Cell metabolism*, 37(5), 1103.

Zhong Y, et al. (2025) Photoconverted cells allow rapid assessment of vaccine adjuvant potency in mice. *iScience*, 28(7), 112774.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. *Cell metabolism*.

Guruprasad P, et al. (2025) Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. *Nature protocols*.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. *Cell*, 188(26), 7591.

Sonehara K, et al. (2025) Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene. *Cell genomics*, 100978.

Shapir Itai Y, et al. (2024) Bispecific dendritic-T cell engager potentiates anti-tumor immunity. *Cell*, 187(2), 375.

Mei D, et al. (2024) Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models. *Journal for immunotherapy of cancer*, 12(9).

Wofford W, et al. (2024) Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response. *Cell reports*, 43(8), 114532.

Cao J, et al. (2024) Deciphering the metabolic heterogeneity of hematopoietic stem cells with single-cell resolution. *Cell metabolism*, 36(1), 209.

Oami T, et al. (2024) Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. *Proceedings of the National Academy of Sciences of the United States of America*, 121(10), e2217877121.

Zhou X, et al. (2023) MHC class II regulation of CD8+ T cell tolerance and implications in autoimmunity and cancer immunotherapy. *Cell reports*, 42(11), 113452.

Gelderblom M, et al. (2023) A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke. *Brain communications*, 5(2), fcad090.

Finlay CM, et al. (2023) T helper 2 cells control monocyte to tissue-resident macrophage differentiation during nematode infection of the pleural cavity. *Immunity*, 56(5), 1064.

Lee H, et al. (2023) Stress-induced β cell early senescence confers protection against type 1 diabetes. *Cell metabolism*, 35(12), 2200.

Fanti AK, et al. (2023) Flt3- and Tie2-Cre tracing identifies regeneration in sepsis from multipotent progenitors but not hematopoietic stem cells. *Cell stem cell*, 30(2), 207.

Hope JL, et al. (2023) PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. *Cell reports*, 42(5), 112436.